Company: PGEN
Filing Date: 2025-03-19
Form Type: 10-K
Source: 0001356090-25-000007
Chunk: 328

Company: PRECIGEN, INC.
Filing Date: 2025-03-19
Form: 10-K
Item: Item 16
Chunk 328
---
 to be disclosed. The CODM uses Segment Adjusted EBITDA for each segment in order to evaluate performance and allocate resources, reviewing actual results to budget throughout the year as an input into making those decisions.For the year ended December 31, 2024, the Company's reportable segments were (i) Biopharmaceuticals and (ii) Exemplar. These identified reportable segments met the quantitative thresholds to be reported separately for the year ended December 31, 2024. See Note 2 for a description of Biopharmaceuticals and Exemplar. Segment Adjusted EBITDA by reportable segment was as follows:

F-42

Year Ended December 31, 2024BiopharmaceuticalsExemplarTotalRevenues from external customers/Total segment revenues$— $3,925 $3,925 Less:Salaries, benefits and other payroll expenses, including severance cost(43,363)(2,879)Rent and Utilities(3,195)(706)Capital Expenditures(8,477)(47)Other Segment Adjusted EBITDA(27,252)(1,222)Segment Adjusted EBITDA$(82,287)$(929)$(83,216)Year Ended December 31, 2023BiopharmaceuticalsExemplarTotalRevenues from external customers/Total segment revenues$75 $6,150 $6,225 Less:Salaries, benefits and other payroll expenses(40,276)(3,774)Rent and Utilities(2,854)(801)Capital Expenditures(1,251)(187)Other Segment Adjusted EBITDA(31,033)(2,114)Segment Adjusted EBITDA$(75,339)$(726)$(76,065)Year Ended December 31, 2022BiopharmaceuticalsExemplarTotalRevenues from external customers/Total segment revenues$14,894 $12,015 $26,909 Less:Salaries, benefits and other payroll expenses(37,624)(3,771)Rent and Utilities(4,093)(745)Capital Expenditures(1,254)(141)Other Segment Adjusted EBITDA(49,465)(2,361)Segment Adjusted EBITDA$(77,542)$4,997 $(72,545)Other Segment EBITDA for each reportable segment in the table above includes:–Biopharmaceuticals